Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Prostatic Neoplasms 29Breast Neoplasms 28Brain Neoplasms 21Neoplasms 16Glioma 10Pancreatic Neoplasms 9Head and Neck Neoplasms 8Lymphoma 7Uterine Cervical Neoplasms 6Urinary Bladder Neoplasms 6Rectal Neoplasms 6Glioblastoma 6Colonic Neoplasms 6Carcinoma, Hepatocellular 6Lymphoma, Non-Hodgkin 5Lung Neoplasms 5Astrocytoma 5Triple Negative Breast Neoplasms 4Squamous Cell Carcinoma of Head and Neck 4Liver Neoplasms 4Disease 4Central Nervous System Neoplasms 4Stomach Neoplasms 3Spinal Cord Neoplasms 3Sarcoma 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Esophageal Neoplasms 3Carcinoma in Situ 3Retinoblastoma 2Pathologic Complete Response 2

Interventions

Cyclophosphamide 87fludarabine 77fludarabine phosphate 45Tacrolimus 45Whole-Body Irradiation 42Mycophenolic Acid 42Busulfan 35Melphalan 32Antilymphocyte Serum 24Methotrexate 23thymoglobulin 22Standard of Care 22Rituximab 22venetoclax 20Thiotepa 20Sirolimus 20Azacitidine 20Stem Cell Transplantation 18Granulocyte Colony-Stimulating Factor 18Practice Guidelines as Topic 17Cytarabine 16Bortezomib 16Nivolumab 15Filgrastim 15Specimen Handling 14Dexamethasone 14Blood Specimen Collection 14Cyclosporine 13Surveys and Questionnaires 12Mesna 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Hematologic Neoplasms × Magnetic Resonance Imaging × Clear all
NCT05371054 2026-02-23

Study of VIP152, Venetoclax, and Prednisone (VVIP) in Relapsed/Refractory Lymphoid Malignancies

National Institutes of Health Clinical Center (CC)

Phase 1/2 Completed
8 enrolled 20 charts
LymphoidOther hematologic neoplasm

Lymphoma, Lymphoma, Non-Hodgkin, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡